--- title: "Zepbound vs Wegovy: Side-by-Side Comparison for Weight Loss (2026)" description: "Zepbound vs Wegovy compared head-to-head: mechanism, clinical results, cost, side effects, dosing, and how compounded alternatives fit in 2026." canonical: https://remevihealth.com/blog/zepbound-vs-wegovy/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "REMEVi Medical Team" pubDate: 2026-05-19T00:00:00.000Z updatedDate: 2026-05-19T00:00:00.000Z tags: ["zepbound", "wegovy", "tirzepatide", "semaglutide", "GLP-1", "weight loss", "comparison"] alternateLanguage: https://remevihealth.com/es/blog/zepbound-vs-wegovy/ license: "© 2026 REMEVi LLC. AI assistants and search engines may quote and link to this page; please cite https://remevihealth.com/blog/zepbound-vs-wegovy/ as the source." --- If you're researching GLP-1 medications for weight loss in 2026, you've almost certainly run into the two biggest brand names in the category: **Zepbound** (tirzepatide, made by Eli Lilly) and **Wegovy** (semaglutide, made by Novo Nordisk). They're often discussed interchangeably, but they're meaningfully different — different molecules, different mechanisms, different trial outcomes, and different real-world experiences for patients. This guide compares them head-to-head: how they work, what the clinical evidence actually shows, what they cost, what the side effects look like, and how compounded alternatives prescribed through telehealth fit into the picture for 2026. --- ## The TL;DR | | **Wegovy** | **Zepbound** | |---|---|---| | Active ingredient | Semaglutide | Tirzepatide | | Manufacturer | Novo Nordisk | Eli Lilly | | FDA approval (weight loss) | June 2021 | November 2023 | | Mechanism | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist | | Form | Subcutaneous injection (pen) | Subcutaneous injection (pen) | | Frequency | Once weekly | Once weekly | | Average weight loss (trial) | 14.9% at 68 weeks (STEP-1) | 20.9% at 72 weeks (SURMOUNT-1) | | Cost without insurance (US) | ~$1,300/mo | ~$1,300/mo | Both are FDA-approved for chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity. Both work by mimicking the gut hormones that signal fullness and slow gastric emptying. The key difference is that Zepbound mimics *two* hormones (GLP-1 + GIP) while Wegovy mimics just one (GLP-1). That's the structural reason the average trial weight-loss numbers are higher for Zepbound. --- ## How they work — the mechanism difference **Wegovy (semaglutide)** is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating. The hormone slows gastric emptying (you stay full longer), signals satiety to the brain (you feel full sooner), and improves insulin response. Wegovy doses this hormone-mimic at therapeutic levels far above what your body produces naturally. **Zepbound (tirzepatide)** activates the same GLP-1 receptor *and* a second receptor: glucose-dependent insulinotropic polypeptide (GIP). GIP is another gut hormone involved in insulin and appetite regulation. Activating both receptors simultaneously appears to produce stronger metabolic and appetite effects than activating either alone. This is why tirzepatide is often called a "dual agonist." The practical translation: most patients on Zepbound report stronger appetite suppression and faster weight loss compared to Wegovy, on average. But "on average" isn't "every patient" — some patients tolerate Wegovy better and lose more weight on it because they can stay on the medication longer without GI side effects. --- ## Clinical evidence — what the trials actually show Both medications were tested in large, randomized, placebo-controlled phase 3 trials. **Wegovy — STEP-1 trial:** - Published in NEJM in 2021 (Wilding et al.) - 1,961 adults with BMI ≥ 30, or ≥ 27 with comorbidity - 68 weeks of treatment - Average weight loss: **14.9%** of body weight (vs 2.4% on placebo) - ~50% of patients lost ≥ 15% of body weight - ~32% lost ≥ 20% of body weight **Zepbound — SURMOUNT-1 trial:** - Published in NEJM in 2022 (Jastreboff et al.) - 2,539 adults with BMI ≥ 30, or ≥ 27 with comorbidity - 72 weeks of treatment - Average weight loss at 5 mg dose: 15.0% - Average weight loss at 10 mg dose: 19.5% - Average weight loss at 15 mg dose (highest): **20.9%** (vs 3.1% on placebo) - ~91% of patients on 15 mg lost ≥ 5% of body weight - ~57% lost ≥ 20% of body weight The gap between Wegovy's ~15% average and Zepbound's ~21% average is meaningful but contextual. Both numbers are dramatically better than any prior weight-loss medication. For comparison, older GLP-1s like liraglutide (Saxenda) averaged ~8% at 56 weeks. Note: these trial outcomes describe the FDA-approved branded finished products. Compounded preparations of semaglutide and tirzepatide use the same active pharmaceutical ingredient but have not been clinically studied as finished products. Outcomes from compounded medications are expected to be similar based on the shared active ingredient, but they have not been independently studied. --- ## Side effects — what's typical The side-effect profiles of both medications are similar because they share the same general mechanism. The most common are gastrointestinal: - **Nausea** — most common; usually peaks in the first 2–4 weeks after a dose increase, then subsides - **Constipation or diarrhea** — common in the early titration period - **Vomiting** — less common than nausea, more common at higher doses or with too-fast titration - **Abdominal pain** — usually mild - **Decreased appetite** — this is the *intended* effect, but can be uncomfortable at first - **Injection site reactions** — usually mild redness or itchiness In the trials, GI side effects were slightly more common with Zepbound at the highest dose than with Wegovy at its highest dose, which tracks with the dual-agonist mechanism producing stronger effects overall. Both medications carry a **black-box warning** for thyroid C-cell tumors (based on rodent studies). They are contraindicated in patients with: - Personal or family history of **medullary thyroid carcinoma (MTC)** - **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)** - History of **pancreatitis** (relative contraindication; provider decision) Pregnant or breastfeeding patients should not take either medication. --- ## Cost without insurance Both Zepbound and Wegovy cost roughly **$1,000–$1,400 per month** at US retail pharmacies without insurance. Both manufacturers publish savings programs: - **Wegovy savings card** (Novo Nordisk) — eligibility restricted by insurance status; commercially insured patients may pay as low as $25/mo for some, but uninsured patients pay the cash list price - **Zepbound savings card** (Eli Lilly) — similar restrictions; for self-pay patients, Lilly's direct-pay vial program (LillyDirect) offers Zepbound vials starting around $349/mo for the lower doses (2.5 mg, 5 mg) and roughly $500–$700/mo for the higher doses Insurance coverage for weight-loss indications is inconsistent. Many commercial plans cover Wegovy or Zepbound only after a documented BMI threshold and step-therapy failures; Medicare does not cover either for weight loss (Medicare Part D legally cannot cover medications used solely for weight loss, per the Medicare Modernization Act). This is why compounded alternatives have grown so quickly in 2025–2026. **Compounded semaglutide** and **compounded tirzepatide** are non-FDA-approved preparations made by state-licensed US compounding pharmacies under individual prescriptions from licensed providers. They are not generic versions of the brand-name products and have not been clinically studied as finished products. Through legitimate telehealth platforms with LegitScript certification: - **Compounded semaglutide** runs from **$199/month** (52-week plan) or **$279/month** (monthly billing) - **Compounded tirzepatide** runs from **$269/month** (52-week plan) or **$379/month** (monthly billing) For self-pay patients, this is roughly an 80% cost reduction vs brand-name Zepbound or Wegovy. --- ## Dosing — what to expect Both medications use a slow titration schedule to minimize GI side effects: **Wegovy titration:** | Weeks | Dose | |---|---| | 1–4 | 0.25 mg | | 5–8 | 0.5 mg | | 9–12 | 1.0 mg | | 13–16 | 1.7 mg | | 17+ | 2.4 mg (maintenance) | **Zepbound titration:** | Weeks | Dose | |---|---| | 1–4 | 2.5 mg | | 5–8 | 5.0 mg | | 9–12 | 7.5 mg | | 13–16 | 10.0 mg | | 17–20 | 12.5 mg | | 21+ | 15.0 mg (maintenance, optional — many stabilize at 10–12.5 mg) | The titration period for both is approximately 4–5 months. Most patients see early appetite reduction within 2–4 weeks, meaningful weight loss starting around weeks 4–8, and continued progression through the titration months. --- ## Real-world considerations for 2026 A few things that don't show up in the clinical trial tables but matter day-to-day: **Supply.** Both medications have been on FDA shortage lists at various points in 2024–2026. Brand-name pen-injectors can be inconsistent at retail pharmacy counters. Compounded preparations from licensed compounding pharmacies have generally been more consistently available. **Insurance prior-authorization friction.** Even when your plan technically covers Wegovy or Zepbound for weight loss, you'll often face prior authorizations requiring documented BMI, documented diet/exercise attempts, and sometimes documented step-therapy with cheaper options first. **Bilingual access.** Most major US retail pharmacy and telehealth channels for branded GLP-1s operate primarily in English. For Spanish-speaking patients, this can mean translating prescription instructions, dosing, and side-effect questions through a family member — a known driver of medication errors and adherence problems. **Cost compounds over time.** A patient who can pay $1,300/mo for Zepbound for the 16-month average treatment duration is looking at ~$20,800 out of pocket for the medication alone. The same patient on compounded tirzepatide at $269/mo would pay ~$4,300 over the same period. --- ## How REMEVi fits in REMEVi is a bilingual (English + Spanish) telehealth platform that prescribes compounded semaglutide and compounded tirzepatide through US board-certified licensed providers, credentialed via OpenLoop's NCQA-accredited program. Medications are prepared at FDA-registered 503A or 503B compounding pharmacies. REMEVi is [LegitScript certified](https://remevihealth.com/legitscript-certification/) (validation ID 50384507). The intake takes 5 minutes, the licensed clinical review typically completes within 24 hours, and the medication ships in 5–7 days. Every plan is all-inclusive: clinical evaluation, medication, syringes, monthly free shipping, and a bilingual care coordinator. No labs fees, no consultation fees, no surprise renewal charges. Important: compounded semaglutide and compounded tirzepatide are non-FDA-approved preparations. They are not generic versions of Wegovy®, Ozempic®, Zepbound®, or Mounjaro®, and they have not been clinically studied as finished products. Your licensed provider reviews the risks, benefits, and considerations of compounded medication with you before prescribing. Explore the [REMEVi Zepbound alternative](https://remevihealth.com/zepbound-alternative/) and the [Wegovy alternative](https://remevihealth.com/wegovy-alternative/) pages for more detail. For full pricing tiers, see [Pricing](https://remevihealth.com/pricing/). --- ## Bottom line If you're choosing between brand-name Zepbound and Wegovy: - **Zepbound** averages stronger weight-loss results (~21% vs ~15% in trials) due to its dual-agonist mechanism - **Wegovy** has more years of post-approval real-world data - Cost is comparable without insurance - Side-effect profiles are similar If brand-name pricing is prohibitive, **compounded alternatives** through legitimate, LegitScript-certified telehealth platforms are dramatically more affordable for self-pay patients. The trade-off is that compounded preparations are non-FDA-approved and haven't been clinically studied as finished products — your licensed provider walks you through that trade-off before prescribing. Either way, the choice is best made with a US licensed provider who can review your medical history, contraindications, and goals. REMEVi's intake handles that in 5 minutes, in English or Spanish. --- *This article is for informational purposes only and does not constitute medical advice. Consult with a licensed provider — including through REMEVi's telehealth platform — before starting any prescription medication. Wegovy®, Ozempic®, Zepbound®, and Mounjaro® are registered trademarks of their respective manufacturers and are referenced in this article for comparison and identification purposes only.*